 |
2-Chloro-4-[1-(4-fluoro-phenyl)-2,5-dimethyl-1H-imidazol-4-ylethynyl]-pyridinium sulfate |
|---|---|
| Trade Name | |
| Orphan Indication | Fragile X syndrome |
| USA Market Approval | USA |
| USA Designation Date | 2012-03-09 00:00:00 |
| Sponsor | Hoffmann-La Roche, Inc.;340 Kingsland Street;Nutley, NJ, 07110-1199 |
